Sagimet Biosciences (SGMT) Operating Leases (2022)

Sagimet Biosciences (SGMT) recorded quarterly Operating Leases of $78000.0 in Q4 2022.

Sagimet Biosciences (SGMT) Operating Leases (2022) Analysis & Trends

Sagimet Biosciences' Operating Leases history runs 1 years deep, the most recent figure standing at $78000.0 for Q4 2022.

In Q4 2022, Operating Leases changed N/A year-over-year to $78000.0; the TTM figure through Dec 2022 stood at $78000.0 (changed N/A YoY), while the FY2022 annual figure was $78000.0, changed N/A from the prior year.
Operating Leases was $78000.0 for Q4 2022 at Sagimet Biosciences.
In the past five years, Operating Leases ranged from a high of $78000.0 in Q4 2022 to a low of $78000.0 in Q4 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Sagimet Biosciences	211.96 Mn	211.96 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2022	78,000.00